 Glioblastoma
"Glioblastoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Descriptor ID |
D005909
|
| MeSH Number(s) |
C04.557.465.625.600.380.080.335 C04.557.470.670.380.080.335 C04.557.580.625.600.380.080.335
|
| Concept/Terms |
Glioblastoma- Glioblastoma
- Glioblastomas
- Astrocytoma, Grade IV
- Astrocytomas, Grade IV
- Grade IV Astrocytoma
- Grade IV Astrocytomas
Giant Cell Glioblastoma- Giant Cell Glioblastoma
- Giant Cell Glioblastomas
- Glioblastoma, Giant Cell
- Glioblastomas, Giant Cell
|
Below are MeSH descriptors whose meaning is more general than "Glioblastoma".
Below are MeSH descriptors whose meaning is more specific than "Glioblastoma".
This graph shows the total number of publications written about "Glioblastoma" by people in this website by year, and whether "Glioblastoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 1997 | 1 | 0 | 1 | | 1998 | 2 | 0 | 2 | | 1999 | 1 | 0 | 1 | | 2000 | 2 | 0 | 2 | | 2001 | 2 | 0 | 2 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 3 | 4 | | 2004 | 1 | 0 | 1 | | 2005 | 3 | 0 | 3 | | 2006 | 5 | 3 | 8 | | 2007 | 3 | 1 | 4 | | 2008 | 2 | 1 | 3 | | 2009 | 1 | 1 | 2 | | 2010 | 6 | 0 | 6 | | 2011 | 2 | 0 | 2 | | 2012 | 8 | 2 | 10 | | 2013 | 11 | 2 | 13 | | 2014 | 13 | 2 | 15 | | 2015 | 15 | 1 | 16 | | 2016 | 12 | 0 | 12 | | 2017 | 14 | 1 | 15 | | 2018 | 17 | 1 | 18 | | 2019 | 12 | 3 | 15 | | 2020 | 17 | 1 | 18 | | 2021 | 15 | 0 | 15 | | 2022 | 18 | 1 | 19 | | 2023 | 18 | 0 | 18 | | 2024 | 6 | 0 | 6 | | 2025 | 12 | 1 | 13 | | 2026 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Glioblastoma" by people in Profiles.
-
Lindsay H, Du Y, Qi L, Zhang H, Zhao S, Braun FK, Kogiso M, Stephan C, Alton G, Stein G, Beaton G, Kesari S, Neuhauser S, Stearns T, Chuang J, Jocoy EL, Bult CJ, Teicher B, Smith MA, Li XN. Targeting Pediatric Glioblastomas by Combining OLIG2 Inhibitor CT-179 with Fractionated Radiation in a Panel of Patient-Derived Orthotopic Xenograft Mouse Models. Int J Mol Sci. 2026 Feb 04; 27(3).
-
Nelson CB, Wells JK, Kesarwani E, Sobinoff AP, Fernando M, Gao J, MacKenzie KL, Poulos RC, Nawaz U, Wang X, Ford HL, Pickett HA. Potent synthetic lethality between PLK1 and EYA family inhibitors in tumors of the central and peripheral nervous systems. Genes Dev. 2026 Feb 02; 40(3-4):267-283.
-
Ajaib S, Winter-Luke J, Digby RJ, Pollock S, Hemmings G, Gusnanto A, Chakrabarty A, Ismail A, Wilson E, Hunter B, Filby A, McDonald D, Brockman AA, Ihrie RA, Stead LF. Spatial profiling of longitudinal glioblastoma reveals consistent changes in cellular architecture, post-treatment. Neuro Oncol. 2025 Dec 01; 27(12):3145-3160.
-
Walton CM, Bell M, O'Neil R, Sahin O, Choi BD, Fecci PE, Strickland BA. Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions. J Immunother Cancer. 2025 Oct 31; 13(10).
-
Zannikou M, Duffy JT, Procissi D, Najem H, Levine RN, Thakur A, Hambardzumyan D, Lee-Chang C, Leoni L, Horbinski CM, Simberg D, Zhang B, Heimberger AB, Miska J, Balyasnikova IV. Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models. J Immunother Cancer. 2025 Oct 28; 13(10).
-
Savage N, Danis E, Chokshi CR, Custers S, Shaikh MV, Miletic P, Venugopal C, Brown KR, Vibhakar R, Moffat J, Singh SK. CRISPR screen reveals SOX2 as a critical regulator of CD133 and cellular stress response in glioblastoma. Sci Rep. 2025 Oct 16; 15(1):36228.
-
Graham-Gurysh EG, Woodring RN, Simpson SR, Mendell SE, Lukesh NR, Pena ES, Moore KM, Ontiveros-Padilla LA, Hendricksen AT, Lopez AM, Williamson GL, Murphy CT, Genito CJ, Hipp KA, Singh G, Zamboni WC, Hingtgen SD, Fecci PE, Bachelder EM, Ainslie KM. Post-resection delivery of a TLR7/8 agonist from a biodegradable scaffold achieves immune-mediated glioblastoma clearance and protection against tumor challenge in mice. Nat Commun. 2025 Sep 29; 16(1):8603.
-
Martin P, Holloway L, Metcalfe P, Koh ES, Aly F, Chan E, Brighi C. Repeatability of diffusion and perfusion MRI derived radiomic features in glioblastoma: a test-retest study. Phys Eng Sci Med. 2025 Dec; 48(4):1691-1702.
-
Mulkearns-Hubert EE, Hajdari N, Hong ES, Jacobs AP, Gaboriau A, Giltner S, Tannish G, Kay KE, Wang SZ, LaViolette PS, Silver DJ, Hubert CG, Dhawan A, Lathia JD. Connexin 43 drives glioblastoma cancer stem cell phenotypes through a WNK lysine-deficient protein kinase 1-c-MYC signaling axis. Cell Rep. 2025 Sep 23; 44(9):116303.
-
Sowers ML, Baljinnyam T, Herring JL, Chang-Gu B, Hackfeld LC, Tang H, Hatch S, Valdes P, Zhang K, Sowers LC. Temozolomide-Derived AIC Is Incorporated into Purine Synthesis in Glioblastoma. Chem Res Toxicol. 2025 Oct 20; 38(10):1698-1707.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|